These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. Jordan VC; O'Malley BW J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378 [TBL] [Abstract][Full Text] [Related]
24. The future of the new selective estrogen receptor modulators. Palacios S Menopause Int; 2007 Mar; 13(1):27-34. PubMed ID: 17448265 [TBL] [Abstract][Full Text] [Related]
25. [Estrogens and selective estrogen receptor modulators in the treatment of osteoporosis]. Ribot C; Tremollieres F; Pouilles JM Ann Med Interne (Paris); 2000 Oct; 151(6):490-6. PubMed ID: 11104929 [TBL] [Abstract][Full Text] [Related]
26. Pharmacology and clinical applications of selective estrogen receptor modulators. Nath A; Sitruk-Ware R Climacteric; 2009 Jun; 12(3):188-205. PubMed ID: 19387883 [TBL] [Abstract][Full Text] [Related]
27. [Effects of SERMs on bone health. Mechanisms of bone mass control by selective estrogen receptor modulator]. Imai Y; Kato S Clin Calcium; 2010 Mar; 20(3):339-44. PubMed ID: 20190363 [TBL] [Abstract][Full Text] [Related]
31. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature. Saji S; Kuroi K Breast Cancer; 2008; 15(4):262-9. PubMed ID: 18654829 [TBL] [Abstract][Full Text] [Related]
32. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. Ho SM J Cell Biochem; 2004 Feb; 91(3):491-503. PubMed ID: 14755680 [TBL] [Abstract][Full Text] [Related]
33. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Gennari L Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205 [TBL] [Abstract][Full Text] [Related]
34. Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. Zhao L; O'Neill K; Diaz Brinton R Brain Res Brain Res Rev; 2005 Nov; 49(3):472-93. PubMed ID: 16269315 [TBL] [Abstract][Full Text] [Related]
35. Raloxifene, tamoxifen and vascular tone. Leung FP; Tsang SY; Wong CM; Yung LM; Chan YC; Leung HS; Yao X; Huang Y Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):809-13. PubMed ID: 17600563 [TBL] [Abstract][Full Text] [Related]
36. Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells. Flamini MI; Sanchez AM; Goglia L; Tosi V; Genazzani AR; Simoncini T Mol Hum Reprod; 2009 Oct; 15(10):675-85. PubMed ID: 19541800 [TBL] [Abstract][Full Text] [Related]
37. Extracellular matrix integrity: a possible mechanism for differential clinical effects among selective estrogen receptor modulators and estrogens? Cox DA; Helvering LM Mol Cell Endocrinol; 2006 Mar; 247(1-2):53-9. PubMed ID: 16426741 [TBL] [Abstract][Full Text] [Related]
38. Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene. Thiebaud D; Secrest RJ Reprod Fertil Dev; 2001; 13(4):331-6. PubMed ID: 11800172 [TBL] [Abstract][Full Text] [Related]
39. [SERMs: an update for clinicians]. Ohta H Clin Calcium; 2005 Apr; 15(4):637-42. PubMed ID: 15802777 [TBL] [Abstract][Full Text] [Related]